Investigated for skin appearance proxies in preclinical and cosmetic-science contexts (texture, firmness, visible tone) without making therapeutic claims
What makes injectable GHK-Cu particularly interesting is that it operates at extremely low concentrations
Secondary effects have been documented on mast cells, endothelial cells (blood vessel formation), and the small population of dermal stem cells associated with the hair follicle bulge 1
Stacking adds complexity, and isolating variables helps you understand what each compound is doing for you personally
Ligament injuries heal more slowly than tendons due to even more limited blood supply and constant mechanical stress during recovery
Month 3, week 14 (cagri 0.25 mg + reta 2 mg) New round of GI tolerability slow gastric emptying via amylin receptor stacks on top of GLP-1 slow gastric emptying Most community sources describe a "second nausea wave" lasting 57 days at the start of cagrilintide, milder than the original retatrutide titration Hunger between meals reportedly drops further amylin signaling is more meal-bound than GLP-1's sustained suppression Month 4 (cagri 0.5 mg + reta 2 mg) Stack feels stable Weight-loss rate may accelerate modestly compared with retatrutide-alone trajectory Community reports describe "smoother" appetite fewer rebound hunger episodes between meals Month 56 (cagri 1.01.7 mg + reta 2 mg) Approaching cagrilintide maintenance (2.4 mg/week is the Phase 3 dose) REDEFINE 1 analog data: this is the period where the cagrilintide+semaglutide arm pulled away from semaglutide alone Subjective effect: "the cagrilintide is working" reports cluster here Month 7+ (cagri 2.4 mg + reta 24 mg) Stack at maintenance Weight loss typically continues at a measurable rate, in line with retatrutide Phase 2 and REDEFINE 1 analog data Some community users titrate retatrutide higher (3 mg, 4 mg/week) at this point if tolerability permits Months 712 Stack at Maintenance This is the period where the stack's overall result accumulates
